Urological second malignant neoplasms in testicular nonseminoma survivors: a population-based analysis

  • PDF / 1,022,324 Bytes
  • 7 Pages / 595.276 x 790.866 pts Page_size
  • 52 Downloads / 173 Views

DOWNLOAD

REPORT


UROLOGY - ORIGINAL PAPER

Urological second malignant neoplasms in testicular nonseminoma survivors: a population‑based analysis Hao Li1 · Chenxing Zhu2 · Jiapei Wu1 · Yuchen Ma1 · Xi Jin1 · Xin Wei1 · Kunjie Wang1 · Hong Li1  Received: 1 August 2020 / Accepted: 14 September 2020 © Springer Nature B.V. 2020

Abstract Purpose  Patients with testicular non-seminomatous germ cell tumors in the modern cisplatin-based chemotherapy era show favorable outcomes, yielding survivors exposed to increased risk of second malignant neoplasms. The carcinogenic effects of cisplatin were well established, and its side effects had shown close connections with the urinary system. The study aimed to evaluate how the characteristics of the primary testicular nonseminoma are associated with urological second malignant neoplasms and survival outcomes. Methods  Using the Surveillance, Epidemiology and End Results database, standardized incidence ratios (SIR) for three major urological tumors including kidney, bladder, and prostate cancer were calculated for 10,734 patients with testicular nonseminoma from 1975 to 2016. The survival analyses were performed using the Kaplan–Meier method and log-rank test, risk factors for overall survival were determined by Cox regression. Results  We identified a total of 197 patients with secondary urological neoplasms. Patients with previous testicular nonseminoma had elevated risk of kidney cancer (SIR 2.13, 95% CI 1.59–2.79), bladder cancer (SIR 1.47, 95% CI 1.07–1.59), and decreased risks of prostate cancer (SIR 0.75, 95% CI 0.61–0.91) compared with the general population. Patients diagnosed with testicular nonseminoma had favorable prognosis with 10-year overall survival reaching 91.8%, and patients with urological second malignant neoplasms showed better prognoses than patients with other second malignant neoplasms (log-rank P